Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for six companies, including Lingke Pharmaceutical, which is required to clarify the legality and compliance of its establishment and shareholding changes [1] - Lingke Pharmaceutical has submitted an application to list on the Hong Kong Stock Exchange, with CITIC Securities and Jianyin International as joint sponsors [1] Group 2 - The CSRC has requested Lingke Pharmaceutical to provide detailed explanations regarding its capital increases and share transfers, including the pricing basis and any potential irregularities or related party transactions [2] - The company must clarify the basis for its recognition of having no controlling shareholder, as well as provide information on shareholder relationships and the calculation of shareholder numbers [2] Group 3 - Lingke Pharmaceutical is required to disclose whether its business involves human stem cell technology and if it has obtained necessary qualifications and licenses for its operations [3] - The company must also clarify the compliance of its overseas investments and foreign exchange registration procedures [3] Group 4 - The company is developing innovative small molecule inhibitors for autoimmune and inflammatory diseases, with a focus on the JAK-STAT signaling pathway [4] - Key products include LNK01001, a second-generation JAK1 inhibitor, and LNK01004, a third-generation pan-JAK inhibitor, targeting autoimmune and inflammatory diseases [4] - The company has established the IsoNova protein degradation platform, which enhances target selectivity and reduces off-target effects, expanding the range of degradable targets [4]